Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;111:391-393
doi: 10.1161/01.CIR.0000155231.94033.E4
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allessie, M.
Right arrow Articles by Harks, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allessie, M.
Right arrow Articles by Harks, E.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cardiomyopathy
*Genes and Gene Therapy
Related Collections
Right arrow Electrophysiology
Right arrow Arrythmias-basic studies
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrowRelated Article

(Circulation. 2005;111:391-393.)
© 2005 American Heart Association, Inc.


Editorial

Gene Therapy for Repair of Cardiac Fibrosis

A Long Way to Tipperary

Maurits Allessie, MD, PhD; Ulrich Schotten, MD, PhD; Sander Verheule, PhD; Erik Harks, PhD

From the Department of Physiology, Cardiovascular Institute Maastricht, University of Maastricht (M.A., U.S., S.V., E.H.), Maastricht, and the Royal Netherlands Academy of Arts and Sciences (M.A.), Amsterdam, the Netherlands.

Correspondence to Prof M.A. Allessie, Department of Physiology, Cardiovascular Research Institute Maastricht, University of Maastricht, PO Box 616, 6200 MD Maastricht, The Netherlands. E-mail m.allessie@fys.unimaas.nl


Key Words: Editorials • aging • calcium • fibrillation • gene therapy


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Because of the increase in life expectancy and a high survival rate after myocardial infarction, cardiac fibrosis is becoming one of the most important problems in cardiology. It is characterized by excessive accumulation of fibrillar collagen in the extracellular space, either because of a loss of cardiomyocytes (replacement fibrosis) and/or as an interstitial response to various chronic cardiovascular diseases such as hypertension, myocarditis, and congestive heart failure (reactive fibrosis).1 In humans, cardiac fibrosis is universal in the aging heart. Activated fibroblasts play a pivotal role in the formation and maintenance of fibrous tissue by the production of various extracellular-matrix proteins, including collagen and fibronectin. It is now recognized that even in areas with long-standing fibrosis, such as postinfarction scars, fibroblasts remain metabolically active.2 Their activity is regulated by various autocrine and paracrine factors, such as angiotensin II, aldosterone, endothelins, cytokines, and growth factors.3 The renin-angiotensin-aldosterone system is considered to be of major importance for the regulation of cardiac fibrosis. Increased tissue levels of angiotensin II have shown to promote, and ACE inhibitors are able to delay the development of, cardiac fibrosis.4,5

See p 394

Interstitial fibrosis reduces the electrical coupling between cardiac myocytes because fibroblasts produce smaller or larger collagenous septa, which electrically insulate cardiac cells or muscle bundles. As a result, the normal myocardial architecture becomes disrupted and is transformed into a pathological substrate characterized by the presence of multiple insulating barriers, which force the depolarization wave to spread nonuniformly. As predicted by computer simulations and demonstrated in cell . . . [Full Text of this Article]


Related Article:

Fibroblasts Can Be Genetically Modified to Produce Excitable Cells Capable of Electrical Coupling
Eddy Kizana, Samantha L. Ginn, David G. Allen, David L. Ross, and Ian E. Alexander
Circulation 2005 111: 394-398. [Abstract] [Full Text]



This article has been cited by other articles:


Home page
J. Physiol.Home page
R. A. Rose, N. Hatano, S. Ohya, Y. Imaizumi, and W. R. Giles
C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide C receptor-mediated signalling
J. Physiol., April 1, 2007; 580(1): 255 - 274.
[Abstract] [Full Text] [PDF]